Xu, Danmei http://orcid.org/0000-0001-8476-9623
Bewicke-Copley, Findlay http://orcid.org/0000-0003-1292-7965
Close, Karina
Okosun, Jessica http://orcid.org/0000-0001-6021-5044
Gale, Robert Peter
Apperley, Jane http://orcid.org/0000-0002-1710-1794
Weinstock, David M. http://orcid.org/0000-0002-8724-3907
Wendel, Hans-Guido http://orcid.org/0000-0001-7166-4670
Fitzgibbon, Jude http://orcid.org/0000-0002-9069-1866
Funding for this research was provided by:
Imperial College London (ACL program, ACL program)
DH | National Institute for Health Research
Lymph&Co - the registered charity in Amsterdam to fund lymphoma research.
Lymph&Co - the registered charity in Amsterdam to fund lymphoma research.
Lymph&Co - the registered charity in Amsterdam to fund lymphoma research.
Lymph&Co - the registered charity in Amsterdam to fund lymphoma research.
Article History
Received: 16 September 2023
Revised: 29 January 2024
Accepted: 2 February 2024
First Online: 13 February 2024
Competing interests
: GS716054 is a pro-drug developed by Gilead Science Inc. MTA was signed between Gilead and Queen Mary University of London (QMUL) where JF was the principal investigator. JF is now an employee of AstraZeneca Inc. DMW, now an employee of Merck and Co., owns equity in Merck and Co., Bantam, Ajax, and Travera, received consulting fees from Astra Zeneca, Secura, Novartis, and Roche/Genentech, and received research support from Daiichi Sankyo, Astra Zeneca, Verastem, Abbvie, Novartis, Abcura, and Surface Oncology. RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.